Articles tagged with Cancer Immunotherapy
Researchers have discovered that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation, and cancer. These cells rely on the receptor to maintain and mount rapid tissue surveillance responses, making them a promising candidate for next-generation cancer immunotherapies.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.
Researchers at Bar-Ilan University and Weizmann Institute successfully engineered immune cells to recognize and attack cancer and viral targets. The enhanced T cells demonstrated stronger immune responses and greater cancer-killing ability, improving survival in mice.
Scientists found that the gene ZMYND8 drives T-cell exhaustion, revealing a new strategy to improve anti-tumor and anti-viral immune responses. Removing ZMYND8 improves anti-tumor and anti-viral responses on its own, and shows potential synergy in combination with immunotherapy.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers from City of Hope have developed a 'plug-and-play' CAR T technology that allows scientists to update engineered cancer-fighting immune cells after treatment. This technology, called meditope, enables the cells to adapt as tumors evolve, helping them to better control the cells and redirect them to attack different types of ...
Researchers identified a link between B cell activity and immunotherapy-related colitis, a common side effect of cancer treatments. Higher B cell levels before treatment were associated with increased colitis risk, and depleting B cells reduced colitis severity.
Researchers identify recurring states of tumor microenvironment that predict response to immunotherapy, finding that early treatment-induced changes can anticipate course of immune response
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
Researchers from Heidelberg University and Charité have identified a subgroup of CAR T cells that predict the success of low-dose therapies. The study found that the presence of highly functional CAR T cells and a healthy immune system before manufacturing begin are crucial for treatment success.
Researchers developed small molecules that activate macrophages to attack cancer cells, weakening the tumor's defenses against the immune system. The molecules, called Phagocytic Synapse Enhancers, were tested in cell cultures and animal models and showed promising results, slowing tumor growth and extending survival.
Cancer cells release natural antioxidants, such as Peroxiredoxin 1, to suppress immune-cell activity and prevent destruction. Removing this antioxidant production enhances the cancer's response to immunotherapy.
A modular nano-adaptor approach tunes T-cell activation to control CD3 activation and prevent toxicity, increasing therapeutic effectiveness in solid tumors. The platform has identified promising lead designs for multispecific nanoantibody configurations.
A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.
A new study shows that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards. CAR-T cells were able to neutralize tumor cells and immune suppression, leading to unprecedented durable tumour control.
Researchers at the University of Massachusetts Amherst have been awarded $2.5 million to adapt their nanoparticle vaccine research to treat existing cancer. The prime-pull approach will deliver immune-activating medicines to both lymph nodes and tumors to create a robust immune response.
Researchers at Charité report significant success in treating severe rheumatoid arthritis with CD19 CAR T cells, reducing disease activity and promoting sustained remission in patients. The treatment targets disease-driving B cells, allowing the immune system to reset and eliminate harmful antibodies.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers at Nagoya University developed a new delivery vehicle for circular RNA (cirRNA) using a novel lipid nanoparticle, FL0445-LNP, which improves the stability and efficacy of mRNA-based therapeutics. The technology has potential applications in cancer vaccines, genome editing, and protein supplements.
Researchers developed a method to inhibit lipid nanoparticle migration into the liver by coating hepatic sinusoidal walls with polyethylene glycol. This coating reduced liver accumulation by several dozen times and increased protein expression in the spleen, promoting safer nanomedicine with lower dosages.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
Scientists at Gladstone Institutes and UCSF discovered a pair of genetic edits that make CAR-T cells more effective against solid tumors. The new CRISPR screening platform enables the study of gene edits on CAR-T cells inside living mice, uncovering therapeutic targets previously missed in conventional cell culture systems.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
A multidisciplinary team of Penn researchers has developed a platform that delivers a combination of cancer-fighting therapies to treat oral squamous cell carcinoma. The findings show that the platform significantly reduces tumor burden and extends survival in aggressive, p53-therapy-resistant cancer models.
Researchers developed a quantum machine learning framework to predict which tumor mutations will trigger an immune response. The Q-CHIPP model outperformed classical computing methods and achieved a significant technical milestone by scaling to full-length peptide modeling on quantum hardware.
Circulating circRNAs show high cell-type and tissue specificity, making them ideal for non-invasive cancer management. They can be detected in multiple body fluids and reflect treatment response, positioning them as functional drivers of therapy resistance.
Dr. Yi Li receives CPRIT funding to develop treatments for solitary fibrous tumor, a rare cancer driven by gene fusions. Researchers are working on novel therapies, including immunotherapy and antisense oligonucleotides, to reduce cancer-causing signal activity.
Research reveals that patients' inherited genetic variants can impact the benefits and toxicity of CAR-T cell therapy for blood cancers. Variants in genes such as STXBP2, ADAMTSL3, and PTPN22 were found to correlate with treatment-related toxicity or enhanced therapeutic activity.
Researchers at Kobe University have successfully created a subclass of T cells that can be used across patients and reproduceably turned back into those T cells. These cells attack and shrink human patient-derived colorectal cancer tumors implanted in mice, offering potential for future systemic therapy.
Researchers at Nagoya University discovered that complement C3 protein acts inside tumors to prevent immunosuppressive cells, improving cancer immunotherapy effectiveness. Higher levels of C3 in tumor tissue were associated with better treatment outcomes and survival rates in patients.
Researchers discover how tumors hijack the thymus to evade immune surveillance by transporting tumor antigens there. Disrupting a specific chemokine receptor may enhance anti-tumor immunity and improve cancer treatment outcomes.
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
University of Minnesota researchers found that certain immune cells, regulatory T cells, prevent helpful T cells from eliminating hidden cancer cells. By combining treatment strategies, they improved the immune response and reduced cancer spread in preclinical models.
Exercise oncology identifies anti-tumor mechanisms that can be translated into therapies independent of exercise itself. Mechanistic insights from exercise research inform translational opportunities in areas like metabolic remodeling, gut microbiome manipulation, and immune signaling.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Researchers from the University of Nebraska-Lincoln have identified a specific gut bacterium, Bacteroides uniformis, and its metabolites that can positively impact the body's immune response to cancer. The study found that these metabolites can suppress tumor growth and boost anti-tumor immunity in mice.
Researchers created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study identified five distinct subtypes, or 'ecotypes,' that capture meaningful insights into signaling pathways and genetic programs not fully explained by disease stage alone.
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. The results point to potential biomarkers that may help identify patients most likely to benefit from this approach.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.
Researchers have developed a microfluidic platform that recreates the complex ecosystem surrounding pancreatic tumors and observed how cells interact dynamically. The findings reveal a critical mechanism that may explain why many therapies fail and point to new therapeutic strategies.
A new AI model called COMPASS improves the prediction of which patients are most likely to respond to cancer immunotherapy drugs, outperforming existing approaches by 8.5 percent. The model makes predictions based on tumor gene activity and provides a rationale for its output.
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
Researchers developed genetically engineered CAR T cells specifically targeting bladder cancer cells and delivered them directly to the bladder via a catheter. This approach shows promise in controlling bladder tumors in mice and may be effective in humans, offering an alternative to life-altering procedures like bladder removal.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
Researchers identified a critical biological difference in glioblastoma development between male and female laboratory models, pinpointing an immune pathway fueled by GABA in females. Blocking this signal improves outcomes in women, but not men.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.